Details

Autor(en) / Beteiligte

• Riedl, M.
• Hinds, D.
• Alvord, T.
• Dosenovic, S.
• Abdelhadi, J.
• Brownrigg, J.
• Camp, C.
• Banerji, A.

Titel

HEALTHCARE RESOURCE UTILIZATION AMONG LANADELUMAB AND SUBCUTANEOUS C1-INHIBITOR CONCENTRATE NEW USERS - RETROSPECTIVE DATABASE STUDY

Ist Teil von

• Annals of allergy, asthma, & immunology, 2022-11, Vol.129 (5), p.S28-S29

Ort / Verlag

Elsevier Inc

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• Three long-term prophylactic therapies (LTPs) have become available in the past five years for hereditary angioedema (HAE) due to C1-inhibitor (C1-INH) deficiency, including two subcutaneous (SC) options: a monoclonal antibody (lanadelumab) and a plasma-derived C1-INH concentrate (SC-C1-INH). However, limited real-world data on these therapies have been reported. Annualized healthcare resource utilization (HCRU), including medication use, and costs of SC-LTP are described among adults starting lanadelumab or SC-C1-INH based on the 180 days before (baseline) and up to 365 days of continuous use after (follow-up) starting therapy, from the IBM MarketScan US insurance claims database. The study population was required to continuously use lanadelumab or SC-C1-INH for =180 days to be in the analysis. 47 lanadelumab and 38 SC-C1-INH subjects were identified. Bradykinin receptor antagonists (∼50% in both cohorts) and intravenous-C1-INH (40% and 58%, respectively) were the most frequent HAE medications filled during baseline. 20–30% of each cohort had no baseline HAE medication fills. Annualized HCRU, including but not limited to acute medication fills and angioedema-associated emergency department (ED) visits/hospitalizations, decreased by >50% between baseline and follow-up (∼10 to 3–4 for acute medication fills; 1–2 to ∼0.5 for ED visits/hospitalizations) [Figure]. Total estimated annualized healthcare costs were $866,639 and $734,460 for the lanadelumab and SC-C1-INH cohorts respectively, with pharmacy costs accounting for >95% of total costs. HAE SC-LTP reduced HCRU by >50%, though did not eliminate prescription fills for acute HAE medication nor angioedema-associated ED/hospital utilization, indicating burden of disease persists despite newer treatments.